Endovascular treatment of tentorial dural arteriovenous fístulas using the transarterial approach as a first-line strategy

Introdução: Nas últimas décadas, o tratamento endovascular (TEV) tornou-se a primeira opção terapêutica para a maioria das fístulas arteriovenosas durais tentoriais (FAVDTs). O TEV é associado a melhores resultados clínicos, entretanto, as taxas de oclusão angiográfica são inferiores em relação a microcirurgia ou tratamento combinado. Objetivo: avaliar a eficácia e a segurança do TEV das FAVDTs usando a via arterial como estratégia de primeira linha. Métodos: foram retrospectivamente revisados dados clínicos e radiológicos de 45 pacientes consecutivos, portadores de FAVDTs, tratados por via endovascular. Resultados clínicos e angiográficos imediatos e seis meses após o procedimento foram avaliados. Regressão logística univariada e multivariada foram realizadas para identificar preditores de oclusão angiográfica após a primeira sessão de TEV e de complicações clínicas. Resultados: a via arterial foi realizada de forma isolada em 40 FAVDTs (88,9%); 37 (82,2%) FAVDTs foram completamente ocluídas após a primeira sessão de TEV e 44 FAVDTs (97,8%) foram ocluídas após a última sessão de tratamento. A detecção de menos de cinco artérias nutridoras foi um preditor para oclusão total após a primeira sessão de TEV (Odds ratio, 18,9; 95% IC 2,06-173,57; p=0,01). Angiografia de controle após seis meses do TEV foi realizada em 41 pacientes e todas as FAVDTs encontravam-se ocluídas. Resultados neurológicos satisfatórios em longo prazo foram observados em 41 pacientes (91,1%). Complicações clínicas ocorreram em sete (15,6%), pacientes sendo relacionadas ao número de artérias acessadas durante o TEV (Odds ratio, 2,53; 95% IC 1,10-5,86; p=0,03). A taxa de mortalidade relacionada ao procedimento foi de 2,2%. Conclusão: a via arterial é um tratamento seguro e eficaz para as FAVDTs.Background: In recent decades, the endovascular approach has become the standard treatment for most tentorial dural arteriovenous fistulas (TDAVFs). Although endovascular treatment (EVT) is associated with better clinical outcomes, the angiographic occlusion rates are lower than those of surgical or combined approaches. Objective: To evaluate the efficacy and safety of EVT for TDAVFs using the transarterial approach (TAA) as a first-line strategy. Methods: Clinical and radiological data of 45 consecutive patients with TDAVFs who underwent EVT at two centers were retrospectively reviewed. Patient demographics and clinical and angiographic data were registered. Postprocedural and 6-month follow-up angiographic and clinical results were evaluated. Univariable and multivariable logistic regression were performed to identify angiographic occlusion predictors after the first session and predictors of clinical complications. Results: An isolated TAA was used for 40 TDAVFs (88.9%). Thirty-seven (82.2%) TDAVFs were completely occluded with a single EVT session, and 44 TDAVFs (97.8%) were completely occluded with the last procedure. Having less than 5 arterial feeders was a predictor for total occlusion after the first treatment session (odds ratio, 18.9; 95% CI 2.06- 173.57; P= .01). Six-month angiographic control was performed in 41 patients, and all TDAVFs were occluded. Long-term good neurological outcomes were observed in 41 patients (91.1%). Clinical complications occurred in seven (15.6%) patients. They were related to the number of accessed arteries to perform TAA (odds ratio, 2.53; 95% CI 1.10-5.86; P= .03). The procedure-related mortality rate was 2.2%. Conclusion: The TAA is a safe and effective treatment for TDAVFs

Dural arteriovenous fistulas with direct cortical venous drainage treated with Onyx®: a case series Fístulas arteriovenosas durais com drenagem cortical direta tratadas com Onyx®: casuística

Dural arteriovenous fistulas (DAVFs) may have aggressive symptoms, especially if there is direct cortical venous drainage. We report our preliminary experience in transarterial embolization of DAVFs with direct cortical venous drainage (CVR) using Onyx®. METHOD: Nine patients with DAVFs with direct cortical venous drainage were treated: eight type IV and one type III (Cognard). Treatment consisted of transarterial embolization using Onyx-18®. Immediate post treatment angiographies, clinical outcome and late follow-up angiographies were studied. RESULTS: Complete occlusion of the fistula was achieved in all patients with only one procedure and injection in only one arterial pedicle. On follow-up, eight patients became free from symptoms, one improved and no one deteriorated. Late angiographies showed no evidence of recurrent DAVF. CONCLUSION: We recommend that transarterial Onyx® embolization of DAVFs with direct cortical venous drainage be considered as a treatment option, while it showed to be feasible, safe and effective.<br>As fistulas arteriovenosas durais (FAVDs) podem se manifestar com sintomas agressivos, especialmente se existe drenagem cortical direta. Relatamos nossa experiência preliminar na embolização transarterial de FAVDs com drenagem cortical direta usando Onyx®. MÉTODO: Nove pacientes com FAVDs com drenagem cortical direta foram tratados: oito do tipo IV e uma do tipo III (Cognard). O tratamento consistiu na embolização transarterial usando Onyx-18®. Angiografias imediatas pós-tratamento, evolução clínica e angiografias de controle tardias foram estudadas. RESULTADOS: A oclusão completa da fístula foi alcançada em todos pacientes através de um só procedimento e injeção em apenas um pedículo arterial. No seguimento, oito pacientes ficaram livres de sintomas, um melhorou e nenhum deteriorou. Angiografias tardias de controle não mostraram evidência de FAVD recorrente. CONCLUSÃO: Nós recomendamos que a embolização transarterial com Onyx® das FAVDs com drenagem cortical direta, seja considerada como uma opção terapêutica, uma vez que mostrou ser factível, segura e efetiva

Global impact of the COVID-19 pandemic on subarachnoid haemorrhage hospitalisations, aneurysm treatment and in-hospital mortality: 1-year follow-up

Background: Prior studies indicated a decrease in the incidences of aneurysmal subarachnoid haemorrhage (aSAH) during the early stages of the COVID-19 pandemic. We evaluated differences in the incidence, severity of aSAH presentation, and ruptured aneurysm treatment modality during the first year of the COVID-19 pandemic compared with the preceding year. Methods: We conducted a cross-sectional study including 49 countries and 187 centres. We recorded volumes for COVID-19 hospitalisations, aSAH hospitalisations, Hunt-Hess grade, coiling, clipping and aSAH in-hospital mortality. Diagnoses were identified by International Classification of Diseases, 10th Revision, codes or stroke databases from January 2019 to May 2021. Results: Over the study period, there were 16 247 aSAH admissions, 344 491 COVID-19 admissions, 8300 ruptured aneurysm coiling and 4240 ruptured aneurysm clipping procedures. Declines were observed in aSAH admissions (-6.4% (95% CI -7.0% to -5.8%), p=0.0001) during the first year of the pandemic compared with the prior year, most pronounced in high-volume SAH and high-volume COVID-19 hospitals. There was a trend towards a decline in mild and moderate presentations of subarachnoid haemorrhage (SAH) (mild: -5% (95% CI -5.9% to -4.3%), p=0.06; moderate: -8.3% (95% CI -10.2% to -6.7%), p=0.06) but no difference in higher SAH severity. The ruptured aneurysm clipping rate remained unchanged (30.7% vs 31.2%, p=0.58), whereas ruptured aneurysm coiling increased (53.97% vs 56.5%, p=0.009). There was no difference in aSAH in-hospital mortality rate (19.1% vs 20.1%, p=0.12). Conclusion: During the first year of the pandemic, there was a decrease in aSAH admissions volume, driven by a decrease in mild to moderate presentation of aSAH. There was an increase in the ruptured aneurysm coiling rate but neither change in the ruptured aneurysm clipping rate nor change in aSAH in-hospital mortality